Skip to main content
HYUNDAI PHARMACEUTICAL CO., LTD logo

HYUNDAI PHARMACEUTICAL CO., LTD — Investor Relations & Filings

Ticker · 004310 ISIN · KR7004310009 KO Manufacturing
Open in API
Filings indexed 184 across all filing types
Latest filing 2022-09-28 Transaction in Own Shar…
Country KR South Korea
Listing KO 004310

About HYUNDAI PHARMACEUTICAL CO., LTD

http://www.hyundaipharm.co.kr/english

HYUNDAI PHARMACEUTICAL CO., LTD. is a company engaged in the research, development, manufacturing, and distribution of pharmaceutical products, medical devices, and health-focused food and beverages. The company's portfolio encompasses a broad range of prescription (ETC) and over-the-counter (OTC) medicines. Key therapeutic areas include dermatology, respiratory and gastrointestinal disorders, as well as treatments for conditions such as hypertension and dementia. With a strong commitment to innovation, the company focuses on the research of new substances and the continuous development of its drug pipeline. It also serves as a strategic partner for global companies, facilitating market entry and collaboration through its business development initiatives.

Recent filings

Filing Released Lang Actions
신탁계약에의한취득상황보고서
Transaction in Own Shares Classification · 100% confidence The document is a 'Report on Acquisition Status by Trust Agreement' (신탁계약등에의한취득상황보고서) filed by Hyundai Pharm Co., Ltd. with the Financial Supervisory Service (FSS). It details the company's purchase of its own shares through a trust contract with Samsung Securities. This type of filing is specifically categorized as 'Transaction in Own Shares' (POS) as it reports the company's buyback activity.
2022-09-28 Korean
반기보고서 (2022.05)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for Hyundai Pharm Co., Ltd. for the period ending May 31, 2022. It contains detailed financial information, business operations, management discussions, and corporate governance data. As it is a comprehensive financial report for a period shorter than a full fiscal year (interim period) and contains substantive financial statements and analysis, it is classified as an Interim/Quarterly Report. H1 2022
2022-07-15 Korean
공정거래자율준수프로그램운영현황(안내공시)
Governance Information Classification · 100% confidence The document is a regulatory disclosure from Hyundai Pharm regarding their 'Compliance Program (CP) Operation Status and Future Plans'. It details internal governance, anti-corruption measures, and ethical management practices. Since it does not fit into specific financial reporting categories like 10-K or IR, and is a formal regulatory announcement filed with the exchange (KRX), it falls under the 'Regulatory Filings' category.
2022-07-14 Korean
주요사항보고서(자기주식취득신탁계약체결결정)
Transaction in Own Shares Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Financial Supervisory Service/Korea Exchange regarding the decision to enter into a trust agreement for the acquisition of treasury shares (자기주식취득 신탁계약 체결 결정). This is a specific corporate action related to share buybacks, which falls under the category of 'Transaction in Own Shares'.
2022-06-23 Korean
투자판단관련주요경영사항
M&A Activity Classification · 100% confidence The document is a regulatory filing from Hyundai Pharm regarding the termination of a technology transfer agreement for a diabetes treatment. It is a specific corporate disclosure of a material event (contract termination) filed with the Korea Exchange (KRX). Since it does not fit into specific categories like M&A (which usually implies a merger or acquisition of a company) or legal proceedings (which usually implies litigation), it falls under the general regulatory filing category for material corporate disclosures.
2022-04-18 Korean
분기보고서 (2022.02)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for Hyundai Pharmaceutical Co., Ltd. for the first quarter of the 59th fiscal year (covering Dec 1, 2021, to Feb 28, 2022). It contains detailed financial information, business operations, management discussions, and governance details, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2022
2022-04-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.